27 August 2020 - Twenty years ago, perhaps the hottest area of drug research was on a class of compounds called Cholesteryl-Ester Transfer Protein inhibitors (CETPi) – drugs that not only lowered LDL-cholesterol but also dramatically increased HDL-cholsterol – the so-called good cholesterol which was believed to be cardioprotective.
In fact, in early clinical trials, these drugs totally remodelled a heart patient’s lipoprotein profile as they more than doubled HDL-cholesterol levels while further lowering LDL-cholesterol by 20% on top of that seen with a statin.